[go: up one dir, main page]

MX2018009524A - Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso. - Google Patents

Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso.

Info

Publication number
MX2018009524A
MX2018009524A MX2018009524A MX2018009524A MX2018009524A MX 2018009524 A MX2018009524 A MX 2018009524A MX 2018009524 A MX2018009524 A MX 2018009524A MX 2018009524 A MX2018009524 A MX 2018009524A MX 2018009524 A MX2018009524 A MX 2018009524A
Authority
MX
Mexico
Prior art keywords
methods
free
arginine
fusion polypeptide
polypeptide compositions
Prior art date
Application number
MX2018009524A
Other languages
English (en)
Other versions
MX421100B (es
Inventor
Ke Gong
Kevin Maloney
Roy Alston
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MX2018009524A publication Critical patent/MX2018009524A/es
Publication of MX421100B publication Critical patent/MX421100B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Aspectos de la invención que están dirigidos a composiciones que contienen polipéptidos exentos de arginina, y a los métodos para tratar trastornos asociados con la inflamación o la respuesta inmune; en particular, el polipéptido es etanercept.
MX2018009524A 2011-07-01 2012-06-29 Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso MX421100B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161504110P 2011-07-01 2011-07-01
PCT/US2012/044988 WO2013006454A1 (en) 2011-07-01 2012-06-29 Arginine - free tnfr : fc- fusion polypeptide compositions and methods of use

Publications (2)

Publication Number Publication Date
MX2018009524A true MX2018009524A (es) 2021-11-16
MX421100B MX421100B (es) 2025-02-10

Family

ID=46579322

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014000093A MX358137B (es) 2011-07-01 2012-06-29 Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso.
MX2018009524A MX421100B (es) 2011-07-01 2012-06-29 Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014000093A MX358137B (es) 2011-07-01 2012-06-29 Composiciones del polipéptido de fusión tnfr: fc exentas de arginina y métodos de uso.

Country Status (13)

Country Link
US (2) US10995130B2 (es)
EP (1) EP2726090B1 (es)
JP (2) JP6463968B2 (es)
KR (1) KR102061355B1 (es)
CN (2) CN103930124B (es)
AU (2) AU2012279205B2 (es)
BR (1) BR112013033671B1 (es)
CA (1) CA2840711C (es)
DK (1) DK2726090T3 (es)
EA (1) EA026226B1 (es)
MX (2) MX358137B (es)
WO (1) WO2013006454A1 (es)
ZA (1) ZA201400490B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
CA2839619C (en) * 2011-06-28 2021-11-16 Inhibrx Llc Serpin fusion polypeptides and methods of use thereof
EA026226B1 (ru) 2011-07-01 2017-03-31 Байоджен Айдек Ма Инк. Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
US10493151B2 (en) 2011-10-18 2019-12-03 Coherus Biosciences, Inc. Etanercept formulations stabilized with sodium chloride
AR088379A1 (es) * 2011-10-18 2014-05-28 Coherus Biosciences Inc Formulaciones de etanercept estabilizadas con iones metalicos
JP6271536B2 (ja) 2012-07-09 2018-01-31 コヒラス・バイオサイエンシズ・インコーポレイテッド 肉眼不可視粒子の著しい低減を示すエタネルセプト製剤
SMT202000147T1 (it) 2012-09-07 2020-05-08 Coherus Biosciences Inc Formulazioni acquose stabili di adalimumab
EA031324B1 (ru) 2012-09-11 2018-12-28 Кохерус Байосайенсис, Инк. Правильно свернутый этанерцепт с высокой чистотой и высоким уровнем выхода
KR101419884B1 (ko) * 2012-11-27 2014-07-16 (주)알테오젠 단백질과 Fc 도메인을 융합한 융합 단백질의 안정화용 조성물
BR112015027764A2 (pt) * 2013-05-02 2017-08-29 Mabxience S A Formulações alternativas para os polipeptídeos de fusão de tnfr: fc
WO2015056613A1 (ja) * 2013-10-15 2015-04-23 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 安定化されたポリペプチド水性製剤
EP2946767B1 (en) 2014-05-23 2016-10-05 Ares Trading S.A. Liquid pharmaceutical composition
EP2946766B1 (en) 2014-05-23 2016-03-02 Ares Trading S.A. Liquid pharmaceutical composition
ES2600488T3 (es) 2014-05-23 2017-02-09 Ares Trading S.A. Composición farmacéutica líquida
US9821059B2 (en) 2014-10-17 2017-11-21 Alteogen Inc. Composition for stabilizing protein and pharmaceutical formulation comprising the same
CA2970577A1 (en) * 2014-12-22 2016-06-30 Ares Trading S.A. Liquid pharmaceutical composition
WO2016149139A1 (en) * 2015-03-13 2016-09-22 Samsung Bioepis Co., Ltd. Anti-tnf-alpha polypeptide composition and use thereof
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
SG11201903521XA (en) 2016-10-21 2019-05-30 Amgen Inc Pharmaceutical formulations and methods of making the same
KR20180046888A (ko) * 2016-10-28 2018-05-09 (주)셀트리온 안정한 약제학적 제제
CA3042126A1 (en) 2018-05-03 2019-11-03 Michael A. Portman Methods of treating kawasaki disease
CN111228225B (zh) * 2018-11-28 2022-08-26 鲁南制药集团股份有限公司 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂
GB201901547D0 (en) * 2019-02-05 2019-03-27 Arecor Ltd Stabilized Fc Fusion protein solutions
WO2023049814A2 (en) * 2021-09-22 2023-03-30 Sirnaomics, Inc. Nanoparticle pharmaceutical compositions with reduced nanoparticle size and improved polydispersity index

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US20010021380A1 (en) 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
AU4363200A (en) 1999-04-19 2000-11-02 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical desorders
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
CN101721362B (zh) * 2002-02-14 2018-07-03 中外制药株式会社 包含抗体的溶液制剂
EP1946776B1 (en) * 2002-02-27 2017-01-18 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
HUE031630T2 (en) * 2002-02-27 2017-07-28 Immunex Corp Stabilized TNFR-Fc containing arginine
KR100471843B1 (ko) 2002-06-11 2005-03-08 현대자동차주식회사 자동차의 아웃사이드 웨더스트립 장착구조
NO346070B1 (no) 2003-02-10 2022-01-31 Biogen Ma Inc Stabil, vandig, farmasøytisk formulering og fremgangsmåte for fremstilling derav.
MXPA05009135A (es) 2003-02-28 2005-10-20 Ares Trading Sa Formulaciones liquidas de las proteinas de union del factor necrosis del tumor.
JP2007521315A (ja) 2003-08-01 2007-08-02 アムジェン インコーポレイテッド 結晶性腫瘍壊死因子レセプター２ポリペプチド
TW200621282A (en) 2004-08-13 2006-07-01 Wyeth Corp Stabilizing formulations
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
US20110046059A1 (en) * 2005-09-06 2011-02-24 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
MX2008013535A (es) * 2006-04-21 2008-10-29 Amgen Inc Agentes amortiguadores para formulaciones biofarmaceuticas.
AU2007309616B2 (en) 2006-10-20 2011-10-06 Amgen Inc. Stable polypeptide formulations
WO2008127975A2 (en) * 2007-04-11 2008-10-23 Alcon Research, Ltd. Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
EP3189831A1 (en) 2007-11-30 2017-07-12 AbbVie Biotechnology Ltd Protein formulations and methods of making same
US20130209465A1 (en) * 2010-07-30 2013-08-15 Arecor Ltd. Stabilized Aqueous Antibody Compositions
EA026226B1 (ru) 2011-07-01 2017-03-31 Байоджен Айдек Ма Инк. Не содержащие аргинина композиции слитого fc-полипептида и способы их применения

Also Published As

Publication number Publication date
EP2726090A1 (en) 2014-05-07
AU2012279205A1 (en) 2014-02-06
ZA201400490B (en) 2017-09-27
DK2726090T3 (da) 2020-01-20
EA026226B1 (ru) 2017-03-31
MX2014000093A (es) 2014-11-12
WO2013006454A1 (en) 2013-01-10
JP6463968B2 (ja) 2019-02-06
AU2017265026B2 (en) 2019-10-24
US11834491B2 (en) 2023-12-05
MX358137B (es) 2018-08-06
AU2017265026A1 (en) 2017-12-07
EA201490195A1 (ru) 2014-04-30
US20210309719A1 (en) 2021-10-07
MX421100B (es) 2025-02-10
CA2840711A1 (en) 2013-01-10
CN103930124B (zh) 2021-05-11
EP2726090B1 (en) 2020-01-01
US10995130B2 (en) 2021-05-04
JP2017186349A (ja) 2017-10-12
KR20140056218A (ko) 2014-05-09
JP2014518276A (ja) 2014-07-28
US20140255400A1 (en) 2014-09-11
AU2012279205B2 (en) 2017-08-31
CN113244374A (zh) 2021-08-13
BR112013033671A2 (pt) 2017-01-24
KR102061355B1 (ko) 2019-12-31
BR112013033671B1 (pt) 2022-10-18
CA2840711C (en) 2023-10-17
CN103930124A (zh) 2014-07-16
NZ620160A (en) 2016-07-29

Similar Documents

Publication Publication Date Title
MX2018009524A (es) Composiciones del polipeptido de fusion tnfr: fc exentas de arginina y metodos de uso.
CL2024003234A1 (es) Polipéptidos modificados y usos de los mismos.
MX2023008559A (es) Proteínas de fusión fc heterodiméricas il15/il15ra.
AR118560A2 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
MX2023013729A (es) Receptores quimericos de flt3 y metodos de uso de los mismos.
AR098465A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN
CO2018002450A2 (es) Proteínas de fusión de gitrl y usos de las mismas
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
GT201400147A (es) Pirimidinas y triazinas fusionadas sustituidas y su uso
EA201791253A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
CO2017000506A2 (es) Receptor quimérico de antígeno cll-1
MX383855B (es) Metodos novedosos.
CL2015002654A1 (es) Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso
EA201891420A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
UY36021A (es) Proteìnas fc multimèricas
MX376324B (es) Proteinas de union a desmogelina 2 (dsg2) y usos de los mismos.
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
MX2017002205A (es) Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
EA202090632A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
UY37456A (es) Inmunoglobulinas y sus usos
EA202091342A3 (ru) Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения
BR112014026740A8 (pt) anticorpo, composição, método para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo
NI201500117A (es) Pirimidinas fusionadas sustituidas con trifluorometilo y sus usos.
EA201391773A1 (ru) Клетки-предшественники мезодермальной линии
MX2016011561A (es) Anticuerpos especificos para el receptor del factor de crecimiento similar a insulina 1 y usos de los mismos.